Journal ArticleDOI
Sequential Phase I and II Trials of Stereotactic Body Radiotherapy for Locally Advanced Hepatocellular Carcinoma
Alexis Bujold,Christine Massey,John Kim,James D. Brierley,Charles Cho,Rebecca Wong,Rob Dinniwell,Zahra Kassam,Jolie Ringash,Bernard Cummings,Jenna Sykes,Morris Sherman,Jennifer J. Knox,Laura A. Dawson +13 more
Reads0
Chats0
TLDR
Results of prospective trials of stereotactic body radiotherapy (SBRT) for hepatocellular carcinoma with strong rationale for studying SBRT for HCC in a randomized trial are described.Abstract:
Purpose To describe outcomes of prospective trials of stereotactic body radiotherapy (SBRT) for hepatocellular carcinoma (HCC). Patients and Methods Two trials of SBRT for patients with active HCC unsuitable for standard locoregional therapies were conducted from 2004 to 2010. All patients had Child-Turcotte-Pugh class A disease, with at least 700 mL of non-HCC liver. The SBRT dose range was 24 to 54 Gy in six fractions. Primary end points were toxicity and local control at 1 year (LC1y), defined as no progressive disease (PD) of irradiated HCC by RECIST (Response Evaluation Criteria in Solid Tumors). Results A total of 102 patients were evaluable (Trial 1, 2004 to 2007: n = 50; Trial 2, 2007 to 2010: n = 52). Underlying liver disease was hepatitis B in 38% of patients, hepatitis C in 38%, alcohol related in 25%, other in 14%, and none in 7%. Fifty-two percent received prior therapies (no prior sorafenib). TNM stage was III in 66%, and 61% had multiple lesions. Median gross tumor volume was 117.0 mL (rang...read more
Citations
More filters
Journal ArticleDOI
Outcomes After Stereotactic Body Radiotherapy or Radiofrequency Ablation for Hepatocellular Carcinoma
Daniel R. Wahl,Matthew H. Stenmark,Yebin Tao,Erqi L. Pollom,Elaine M. Caoili,Theodore S. Lawrence,Matthew J. Schipper,Mary Feng +7 more
TL;DR: Although these data are retrospective, SBRT appears to be a reasonable first-line treatment of inoperable, larger HCC, and inverse probability of treatment weighting to adjust for imbalances in treatment assignment is applied.
Journal ArticleDOI
Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition).
Jian Zhou,Hui-Chuan Sun,Zheng Wang,Wenming Cong,Jian-Hua Wang,Mengsu Zeng,Weiping Zhou,Ping Bie,Lianxin Liu,Tianfu Wen,Guohong Han,Maoqiang Wang,Ruibao Liu,Li Gong Lu,Zhengang Ren,Minshan Chen,Zhaochong Zeng,Ping Liang,Changhong Liang,Min Chen,Fuhua Yan,Wenping Wang,Yuan Ji,Jingping Yun,Dingfang Cai,Yongjun Chen,Wenwu Cheng,Shu-Qun Cheng,Chaoliu Dai,Wenzhi Guo,Baojin Hua,Xiaowu Huang,Wei-Dong Jia,Yaming Li,Yexiong Li,Jun Liang,Tianshu Liu,Guoyue Lv,Yilei Mao,Tao Peng,Wei Xin Ren,Hongcheng Shi,Guoming Shi,Kaishan Tao,Wentao Wang,Xiaoying Wang,Zhiming Wang,Bangde Xiang,Baocai Xing,Jian Ming Xu,Jiamei Yang,Jianyong Yang,Yefa Yang,Yunke Yang,Shenglong Ye,Zhengyu Yin,Bixiang Zhang,Boheng Zhang,Leida Zhang,Shuijun Zhang,Ti Zhang,Yongfu Zhao,Honggang Zheng,Jiye Zhu,Kangshun Zhu,Rong Liu,Yinghong Shi,Yongsheng Xiao,Zhi Dai,Gaojun Teng,Jianqiang Cai,Weilin Wang,Xiujun Cai,Qiang Li,Feng Shen,Shukui Qin,Jiahong Dong,Jia Fan +77 more
TL;DR: The new guidelines were endorsed and promulgated by the Bureau of Medical Administration of the National Health Commission of the People’s Republic of China in December 2019 and reflect the real-world situation in China regarding diagnosing and treating liver cancer in recent years.
Journal ArticleDOI
Hepatobiliary cancers, Version 2.2021
Al B. Benson,Michael I. D’Angelica,Daniel E. Abbott,Daniel A. Anaya,Robert A. Anders,Chandrakanth Are,Melinda Bachini,Mitesh J. Borad,Daniel B. Brown,Adam M. Burgoyne,Prabhleen Chahal,Daniel T. Chang,Jordan M. Cloyd,Anne M. Covey,Evan S. Glazer,Lipika Goyal,William G. Hawkins,Renuka Iyer,Rojymon Jacob,R. Kate Kelley,Robin D. Kim,Matthew H. Levine,Manisha Palta,James O. Park,Steven S. Raman,Sanjay S. Reddy,Vaibhav Sahai,Tracey E. Schefter,Gagandeep Singh,Stacey Stein,Jean Nicolas Vauthey,Alan P. Venook,Adam C. Yopp,Nicole R. McMillian,Cindy Hochstetler,Susan Darlow +35 more
TL;DR: The NCCN Guidelines for Hepatobiliary Cancers focus on the screening, diagnosis, staging, treatment, and management of hepatocellular carcinoma (HCC), gallbladder cancer, and cancer of the bile ducts as discussed by the authors.
Journal ArticleDOI
Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.
Theodore S. Hong,Jennifer Y. Wo,Beow Y. Yeap,Edgar Ben-Josef,Erin McDonnell,Lawrence S. Blaszkowsky,Eunice L. Kwak,Jill N. Allen,Jeffrey W. Clark,Lipika Goyal,Janet E. Murphy,Milind Javle,John A. Wolfgang,Lorraine C. Drapek,Ronald S. Arellano,Harvey J. Mamon,John T. Mullen,Sam S. Yoon,Kenneth K. Tanabe,Cristina R. Ferrone,David P. Ryan,Thomas F. DeLaney,Christopher H. Crane,Andrew X. Zhu +23 more
TL;DR: High-dose hypofractionated proton therapy demonstrated high LC rates for H CC and ICC safely, supporting ongoing phase III trials of radiation in HCC and ICC.
Journal ArticleDOI
Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A Randomized Clinical Trial.
Sang Min Yoon,Baek-Yeol Ryoo,So Jung Lee,Jong Hoon Kim,Ji Hoon Shin,Jihyun An,Han Chu Lee,Young-Suk Lim +7 more
TL;DR: First-line treatment with TACE plus RT was well tolerated and provided an improved progression-free survival, objective response rate, time to progression, and overall survival compared with sorafenib treatment for patients with advanced hepatocellular carcinoma.
References
More filters
Journal ArticleDOI
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008.
TL;DR: The results for 20 world regions are presented, summarizing the global patterns for the eight most common cancers, and striking differences in the patterns of cancer from region to region are observed.
Journal ArticleDOI
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
Elizabeth Eisenhauer,P. Therasse,Jan Bogaerts,Lawrence H. Schwartz,Daniel J. Sargent,Robert Ford,Janet Dancey,S. Arbuck,S. Gwyther,Margaret M. Mooney,Larry Rubinstein,Lalitha K. Shankar,Lori E. Dodd,Robert M. Kaplan,Denis Lacombe,Jaap Verweij +15 more
TL;DR: The revised RECIST includes a new imaging appendix with updated recommendations on the optimal anatomical assessment of lesions, and a section on detection of new lesions, including the interpretation of FDG-PET scan assessment is included.
Journal ArticleDOI
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Jason P. Fine,Robert Gray +1 more
TL;DR: This article proposes methods for combining estimates of the cause-specific hazard functions under the proportional hazards formulation, but these methods do not allow the analyst to directly assess the effect of a covariate on the marginal probability function.
Journal ArticleDOI
Sorafenib in Advanced Hepatocellular Carcinoma
Josep M. Llovet,Sergio Ricci,Vincenzo Mazzaferro,Philip Hilgard,Edward Gane,Jean-Frédéric Blanc,André Cosme de Oliveira,Armando Santoro,Jean-Luc Raoul,Alejandro Forner,Myron Schwartz,Camillo Porta,Stefan Zeuzem,Luigi Bolondi,Tim F. Greten,Peter R. Galle,Jean Francois Seitz,Ivan Borbath,Dieter Häussinger,Tom Giannaris,Minghua Shan,M. Moscovici,D. Voliotis,Jordi Bruix +23 more
TL;DR: In patients with advanced hepatocellular carcinoma, median survival and the time to radiologic progression were nearly 3 months longer for patients treated with sorafenib than for those given placebo.
Related Papers (5)
Sorafenib in Advanced Hepatocellular Carcinoma
Josep M. Llovet,Sergio Ricci,Vincenzo Mazzaferro,Philip Hilgard,Edward Gane,Jean-Frédéric Blanc,André Cosme de Oliveira,Armando Santoro,Jean-Luc Raoul,Alejandro Forner,Myron Schwartz,Camillo Porta,Stefan Zeuzem,Luigi Bolondi,Tim F. Greten,Peter R. Galle,Jean Francois Seitz,Ivan Borbath,Dieter Häussinger,Tom Giannaris,Minghua Shan,M. Moscovici,D. Voliotis,Jordi Bruix +23 more